コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rget for the development of HFpEF therapy in cardiovascular medicine.
2 c angiogenesis) is a an exciting frontier of cardiovascular medicine.
3 ty of these approaches within the context of cardiovascular medicine.
4 ury, present major therapeutic challenges in cardiovascular medicine.
5 ors hold tremendous promise for the field of cardiovascular medicine.
6 uate current recommendations for training in cardiovascular medicine.
7 nical decision-making and prognostication in cardiovascular medicine.
8 and its treatment is a crucial challenge of cardiovascular medicine.
9 dial infarction (MI) remain an unmet need in cardiovascular medicine.
10 orary randomized controlled trials (RCTs) in cardiovascular medicine.
11 dress key unmet clinical diagnostic needs in cardiovascular medicine.
12 of the most important scientific journals in cardiovascular medicine.
13 f the ongoing transformative effect of AI on cardiovascular medicine.
14 aracterization and personalized therapies in cardiovascular medicine.
15 and impact of patient-centered care in adult cardiovascular medicine.
16 esis and regeneration, potentially informing cardiovascular medicine.
17 to new therapies and advances in reparative cardiovascular medicine.
18 d over the last 12 months and are related to cardiovascular medicine.
19 021 on the role of cardiovascular imaging in cardiovascular medicine.
20 h technology-driven interventions redefining cardiovascular medicine.
21 from disease modelling to drug discovery in cardiovascular medicine.
22 facilitate the success of fibrosis-directed cardiovascular medicine.
23 ovide an opportunity for advancing precision cardiovascular medicine.
24 2004 under the name Nature Clinical Practice Cardiovascular Medicine.
25 a vision for social media and the future of cardiovascular medicine.
26 CRISPR-Cas9 is to be used in the practice of cardiovascular medicine.
27 s already known about specific treatments in cardiovascular medicine.
28 re needed to build the best evidence base in cardiovascular medicine.
29 llowing injury represents a major barrier in cardiovascular medicine.
30 th of advanced infection-targeted imaging in cardiovascular medicine.
31 nty and change attitudes about treatments in cardiovascular medicine.
32 vidence on herbal medications mostly used in cardiovascular medicine.
33 ially affect diagnostics and therapeutics in cardiovascular medicine.
34 ial for more refined, targeted approaches to cardiovascular medicine.
35 o discover unknown drug-drug interactions in cardiovascular medicine.
36 the heart has the potential to revolutionize cardiovascular medicine.
37 D risk is a key new question in the field of cardiovascular medicine.
38 properties have remained at the forefront of cardiovascular medicine.
39 utic regiments, paving the way for precision cardiovascular medicine.
40 en significant areas of research interest in cardiovascular medicine.
41 frailty has become a high-priority theme in cardiovascular medicine.
42 ting and important questions in the field of cardiovascular medicine.
43 that illuminates new therapeutic promise in cardiovascular medicine.
44 e on how to incorporate genetic testing into cardiovascular medicine.
45 s injection is a major clinical challenge in cardiovascular medicine.
46 health monitoring and remote diagnostics in cardiovascular medicine.
47 ardiac tissue has the potential to transform cardiovascular medicine.
48 lar function and their clinical relevance to cardiovascular medicine.
49 ty of radiation use in the practice of adult cardiovascular medicine.
50 nome and exome sequencing in the practice of cardiovascular medicine.
51 ng toward a therapeutic goal of regenerative cardiovascular medicine.
52 ng faces to fulfill its promises in clinical cardiovascular medicine.
53 f high-powered, comprehensive, personalized, cardiovascular medicine.
54 and novel approaches for human regenerative cardiovascular medicine.
55 ndation for novel approaches in regenerative cardiovascular medicine.
56 e critical role of body size measurements in cardiovascular medicine.
57 sceptibility testing, and prognostication in cardiovascular medicine.
58 eat promise for transforming the practice of cardiovascular medicine.
59 ellular matrix components, and drugs used in cardiovascular medicine.
60 o the beneficial effects of beta-blockers in cardiovascular medicine.
61 ly become the next horizon for strategies in cardiovascular medicine.
62 ial therapeutic opportunities for ghrelin in cardiovascular medicine.
63 rombin and its receptors to the forefront of cardiovascular medicine.
64 en focused on quality than in other areas of cardiovascular medicine.
65 technique and suggest future applications in cardiovascular medicine.
66 d new avenues of opportunity in the field of cardiovascular medicine.
67 n important limitations and implications for cardiovascular medicine.
68 herapeutic techniques under investigation in cardiovascular medicine.
69 ve been immensely successful in creating new cardiovascular medicines.
70 histology, embryology, and adipogenesis) and cardiovascular medicine; 3) outlines the anatomic, funct
71 ialties of radiology (692 devices [76.6.%]), cardiovascular medicine (91 devices [10.1%]), and neurol
72 ation between fundamental cancer biology and cardiovascular medicine, a set of metabolic observations
76 d consensus opinion among leading experts in cardiovascular medicine and hypertension research with r
77 ford in 1990 as the Chief of the Division of Cardiovascular Medicine and later became Chairman of the
78 at the unique drivers of burnout in academic cardiovascular medicine and propose system-level and per
79 le examines the past 15 years of progress in cardiovascular medicine and proposes a forward-looking r
80 ng the widespread use of wearable devices in cardiovascular medicine and provide short- and long-term
81 ertise in critical care, pulmonary medicine, cardiovascular medicine and surgery, pediatrics, nursing
82 emerging protein engineering technologies to cardiovascular medicine and the barriers that must be ov
84 ghlight 10 significant MESA contributions to cardiovascular medicine, and chart the path forward for
85 f PROs in shared clinical decision-making in cardiovascular medicine, and concerning future direction
86 rapeutic insights relevant to hematology and cardiovascular medicine, and further advances can be ant
88 cs is a rapidly evolving subspecialty within cardiovascular medicine, and its growth is attributed to
89 ial media practices in academic and clinical cardiovascular medicine; and 3) present a vision for soc
90 nically developed as a new discipline within cardiovascular medicine as a result of the cardiac and v
91 ity have the potential to hinder progress in cardiovascular medicine as preclinical research often pr
92 lliam Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.
93 wpoints on the topic of device innovation in cardiovascular medicine at the European Society of Cardi
95 n deficiency (NAID) is a strategic target in cardiovascular medicine because of its association with
96 nancial conflicts of interest, ubiquitous in cardiovascular medicine because of significant investiga
98 tificial intelligence (AI) holds promise for cardiovascular medicine but is limited by a lack of larg
99 haemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of th
100 ise of becoming a key diagnostic modality in cardiovascular medicine by allowing visualization of spe
101 tly been noteworthy advances in the field of cardiovascular medicine, cardiovascular case fatalities
102 the context of the Century Health Study for Cardiovascular Medicine (Century Trial), a 1,300-patient
103 hock (CS) remains a significant challenge in cardiovascular medicine, characterized by substantial mo
104 the benefits of clinical genetic testing in cardiovascular medicine, clinicians must implement sever
107 view adds an impetus to all practitioners of cardiovascular medicine, especially specialists in HF, t
108 The use of risk markers has transformed cardiovascular medicine, exemplified by the routine asse
109 vide insight into the future of personalized cardiovascular medicine from a regulatory perspective.
111 r such an approach has never been greater in cardiovascular medicine, given the large number of guide
112 e past decade, the implementation of XR into cardiovascular medicine has flourished such that it is n
114 Importantly, recent advances in the field of cardiovascular medicine have not led to significant decl
115 scribed as the 'single largest unmet need in cardiovascular medicine', heart failure with preserved e
116 ingle most important observation in clinical cardiovascular medicine in 1995 was the reporting of a h
119 njection (DHI) is one of the most prescribed cardiovascular medicines in China, its therapeutic indic
120 mportant associations of pharmacogenomics in cardiovascular medicine include clopidogrel and risk for
121 idence supporting pharmacogenetic testing in cardiovascular medicine, including that available from s
122 nterrogated a number of relevant advances in cardiovascular medicine, including widespread fee-for-se
123 an international group of representatives of cardiovascular medicine, interventional radiology, vascu
129 ates has never been rigorously addressed for cardiovascular medicine journals using a randomized desi
130 s suggest that efforts to reduce inequity in cardiovascular medicine may need to include increasing a
131 ere is growing evidence that the practice of cardiovascular medicine might soon have a new toolbox to
132 were selected by NHLBI staff and represented cardiovascular medicine, obstetrics, immunology, and pat
134 ion, although a cornerstone of emergency and cardiovascular medicine, often results in hyperoxia, a c
135 Fast all-optical PAT may prove useful in cardiovascular medicine, oncology, dermatology and rheum
136 tly emerged as a novel therapeutic option in cardiovascular medicine owing to its anti-inflammatory p
137 cial media strategy of Twitter promotion for cardiovascular medicine papers seems to be associated wi
138 ogy completed this white paper to inform the cardiovascular medicine profession regarding the plight
139 d and rationale for patient-centered care in cardiovascular medicine, provides insight into patient-o
140 sessed 303 consecutive superiority trials of cardiovascular medicine published between January 1, 200
141 sed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologi
142 t unmet diagnostic needs in central areas of cardiovascular medicine, such as heart failure, arrhythm
144 thin specialty subgroups (cardiorespiratory, cardiovascular, medicine, surgery, neurology), then chan
145 h a model would serve as a basic approach to cardiovascular medicine that is necessary, but not suffi
147 the right ventricle (RV) in many aspects of cardiovascular medicine, there has been surprisingly lit
148 considered to be the greatest unmet need in cardiovascular medicine today because of a general lack
152 reviews, we summarize advances in access to cardiovascular medicines using the 5 health system dimen
154 ry interface of bioinformatics and precision cardiovascular medicine, which we refer to as 'cardioinf
156 e most widely discussed and debated topic in cardiovascular medicine, with its incidence increasing d
157 rt of the activity of the European Renal and Cardiovascular Medicine working (EURECAm) group and all